造影超音波市場 : 2028年までの世界予測

Report Overview

The global contrast-enhanced ultrasound market is projected to reach USD 2.1 billion by 2028 from USD 1.6 billion in 2023, at a CAGR of 6.1% from 2023 to 2028. Factors such as rising geriatric population and increasing use of contrast agents are responsible for the increasing growth of this market. Increasing research and development activities, government initiatives, and the rising number of clinical trials also contribute to the growth of the contrast-enhanced ultrasound market.

“The equipment segment held the largest share of the market in 2022.”
Based on equipment, the contrast-enhanced ultrasound market is segmented into equipment, contrast agents, and software and services. The contrast-enhanced ultrasound equipment segment held the largest market share in 2022. The large share of this segment can be attributed to the launch of technologically advanced systems and the rising use of contrast-enhanced ultrasound systems by end users.

“The therapeutic applications segment is projected to register the highest CAGR during the forecast period.”
Based on application, the contrast-enhanced ultrasound market is segmented into diagnostic applications and therapeutic applications. The therapeutic application segment is projected to register the highest CAGR from 2023 to 2028. Factors such as the increasing use of contrast agents for targeted drug delivery and patient monitoring are driving market growth.

“The market in the Asia Pacific region is expected to witness the highest growth during the forecast period.”
The contrast-enhanced ultrasound market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and the increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India, is evolving at a rapid pace, leading to major investments in advanced imaging systems by hospitals and diagnostic centers. These factors are anticipated to fuel the growth of the contrast-enhanced ultrasound market in this region.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Rest of the World-8%

The prominent players in the contrast-enhanced ultrasound market are GE Healthcare (US), Lantheus Holdings, Inc. (US), Bracco Imaging SpA (Italy), and Koninklijke Philips N.V. (Netherlands), among others.

Research Coverage

This report studies the contrast-enhanced ultrasound market based on product, application, end-user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall contrast-enhanced ultrasound market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:
• Analysis of key drivers (growing prevalence of chronic diseases, technological advancements, and rising partnerships and collaborations between market players), restraints (side effects of contrast agents), opportunities (growth opportunities in emerging countries and rising number of hospitals and diagnostic imaging centers), and challenges (shortage of skilled sonographers and presence of alternative techniques) influencing the growth of the contrast-enhanced ultrasound market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the contrast-enhanced ultrasound market
• Market Development: Comprehensive information about lucrative markets–the report analyses the contrast-enhanced ultrasound market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the contrast-enhanced ultrasound market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like GE Healthcare (US), Lantheus Holdings, Inc. (US), Bracco Imaging SpA (Italy), Koninklijke Philips N.V. (Netherlands), Siemens Healthcare GmbH (Germany), Shenzen Mindary Bio-Medical Electronics Co, Ltd. (China).

Table of Contents

1 INTRODUCTION 23
1.1 STUDY OBJECTIVES 23
1.2 MARKET DEFINITION 23
1.2.1 INCLUSIONS AND EXCLUSIONS 23
1.3 MARKET SEGMENTATION 24
1.3.1 MARKETS COVERED 24
1.3.2 REGIONS COVERED 24
1.4 YEARS CONSIDERED 25
1.5 CURRENCY CONSIDERED 25
1.6 LIMITATIONS 25
1.7 STAKEHOLDERS 26
1.8 SUMMARY OF CHANGES 26
1.9 RECESSION IMPACT 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
FIGURE 1 CONTRAST-ENHANCED ULTRASOUND MARKET: RESEARCH DESIGN METHODOLOGY 28
2.1.1 SECONDARY RESEARCH 29
2.1.2 PRIMARY RESEARCH 30
2.1.2.1 Primary sources 30
2.1.2.2 Key industry insights 31
2.1.2.3 Breakdown of primaries 31
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 31
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 32
2.2 MARKET SIZE ESTIMATION 32
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 33
2.2.1 BOTTOM-UP APPROACH 34
2.2.1.1 Approach 1: Company revenue estimation approach 34
FIGURE 5 MARKET SIZE ESTIMATION FOR CONTRAST-ENHANCED ULTRASOUND MARKET: APPROACH 1 (COMPANY REVENUE ESTIMATION) 34
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF GE HEALTHCARE 35
2.2.1.2 Approach 2: Customer-based market estimation 35
FIGURE 7 BOTTOM-UP APPROACH FOR MARKET SIZE ESTIMATION 36
2.2.1.3 Growth forecast 36
2.2.1.4 CAGR projections 37
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
 
2.3 DATA TRIANGULATION APPROACH 38
FIGURE 9 DATA TRIANGULATION METHODOLOGY 38
2.4 MARKET ASSUMPTIONS 39
2.5 RISK ASSESSMENT 39
2.5.1 RISK ASSESSMENT ANALYSIS 39
2.6 GROWTH RATE ASSUMPTIONS 40
2.7 RECESSION IMPACT ANALYSIS 40
3 EXECUTIVE SUMMARY 41
FIGURE 10 CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 41
FIGURE 11 CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 42
FIGURE 12 CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 43
FIGURE 13 CONTRAST-ENHANCED ULTRASOUND MARKET: GEOGRAPHIC SNAPSHOT 44
4 PREMIUM INSIGHTS 45
4.1 CONTRAST-ENHANCED ULTRASOUND MARKET OVERVIEW 45
FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 45
4.2 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 46
FIGURE 15 CONTRAST AGENTS SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 46
4.3 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2023 VS. 2028 47
FIGURE 16 THERAPEUTIC APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 47
4.4 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER 48
FIGURE 17 HOSPITALS AND SURGICAL CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 48
4.5 CONTRAST-ENHANCED ULTRASOUND MARKET: GEOGRAPHICAL SNAPSHOT 49
FIGURE 18 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 19 CONTRAST-ENHANCED ULTRASOUND MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Increasing incidence of chronic diseases 51
5.2.1.2 Rising technological advancements in contrast-enhanced ultrasound systems 51
5.2.1.3 Increasing initiatives for commercialization of diagnostic imaging equipment 52
5.2.2 RESTRAINTS 53
5.2.2.1 Risks associated with contrast agents 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Growth opportunities in emerging economies 53
5.2.3.2 Increasing establishment of hospitals and diagnostic imaging centers 54
5.2.4 CHALLENGES 54
5.2.4.1 Shortage of skilled sonographers 54
5.2.4.2 Presence of alternative techniques 54
5.3 PORTER’S FIVE FORCES ANALYSIS 55
TABLE 1 CONTRAST-ENHANCED ULTRASOUND MARKET: PORTER’S FIVE FORCES ANALYSIS 55
5.3.1 THREAT OF NEW ENTRANTS 55
5.3.2 THREAT OF SUBSTITUTES 55
5.3.3 BARGAINING POWER OF SUPPLIERS 55
5.3.4 BARGAINING POWER OF BUYERS 56
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 56
5.4 TRADE ANALYSIS 56
TABLE 2 IMPORT DATA FOR ULTRASOUND SYSTEMS, BY COUNTRY, 2018–2022 (USD THOUSAND) 56
TABLE 3 EXPORT DATA FOR ULTRASOUND SYSTEMS, BY COUNTRY, 2018–2022 (USD THOUSAND) 57
TABLE 4 IMPORT DATA FOR CONTRAST AGENTS, BY COUNTRY, 2018–2022 (USD THOUSAND) 57
TABLE 5 EXPORT DATA FOR CONTRAST AGENTS, BY COUNTRY, 2018–2022 (USD THOUSAND) 58
5.5 PATENT ANALYSIS 58
FIGURE 20 TOP 10 PATENT APPLICANTS (JANUARY 2012–DECEMBER 2022) 59
5.6 ECOSYSTEM COVERAGE OF PARENT MARKET 60
5.7 VALUE CHAIN ANALYSIS 60
5.7.1 RESEARCH & DEVELOPMENT 60
5.7.2 MANUFACTURING & ASSEMBLY 60
5.7.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 60
FIGURE 21 VALUE CHAIN ANALYSIS 61
5.8 SUPPLY CHAIN ANALYSIS 61
5.8.1 PROMINENT COMPANIES 61
5.8.2 SMALL & MEDIUM-SIZED ENTERPRISES 61
5.8.3 END USERS 61
FIGURE 22 SUPPLY CHAIN ANALYSIS 62
5.9 PRICING TREND ANALYSIS 62
TABLE 6 AVERAGE SELLING PRICE FOR MAJOR CONTRAST-ENHANCED ULTRASOUND EQUIPMENT 62
5.10 TECHNOLOGY ANALYSIS 63
5.11 REGULATORY LANDSCAPE 63
5.11.1 NORTH AMERICA 63
5.11.1.1 US 63
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION 64
TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 64
5.11.1.2 Canada 65
TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.11.2 EUROPE 65
5.11.3 ASIA PACIFIC 66
5.11.3.1 Japan 66
TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 66
5.11.3.2 China 67
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES 67
5.11.3.3 India 68
5.12 REIMBURSEMENT SCENARIO 69
TABLE 12 MEDICAL REIMBURSEMENT CODES FOR CONTRAST-ENHANCED ULTRASOUND PROCEDURES 69
5.13 CASE STUDIES 70
5.13.1 TECHNICAL CHALLENGES WITH ULTRASOUND SYSTEMS 70
TABLE 13 CASE STUDY 1: IMPROVED SENSITIVITY AND BETTER VISIBILITY OF BLOOD FLOW 70
5.14 KEY CONFERENCES AND EVENTS 70
TABLE 14 CONTRAST-ENHANCED ULTRASOUND MARKET: LIST OF MAJOR CONFERENCES AND EVENTS (2023–2024) 70
6 CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE 72
6.1 INTRODUCTION 73
TABLE 15 CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 73
6.2 EQUIPMENT 73
6.2.1 INNOVATIVE PRODUCT LAUNCHES WITH IMPROVED DIAGNOSIS AND REAL-TIME MONITORING ABILITIES TO DRIVE MARKET 73
TABLE 16 CONTRAST-ENHANCED ULTRASOUND MARKET FOR EQUIPMENT, BY REGION, 2021–2028 (USD MILLION) 74
6.3 CONTRAST AGENTS 74
TABLE 17 CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 75
TABLE 18 CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY REGION, 2021–2028 (USD MILLION) 75
6.3.1 MOLECULE-TARGETED MICROBUBBLES 75
6.3.1.1 Rising use in targeted therapies to drive market 75
TABLE 19 CONTRAST-ENHANCED ULTRASOUND MARKET FOR MOLECULE-TARGETED MICROBUBBLES, BY REGION, 2021–2028 (USD MILLION) 76
6.3.2 NANOPARTICLE MICROBUBBLES 76
6.3.2.1 Utilization in thermal therapies to fuel market 76
TABLE 20 CONTRAST-ENHANCED ULTRASOUND MARKET FOR NANOPARTICLE MICROBUBBLES, BY REGION, 2021–2028 (USD MILLION) 77
6.4 SOFTWARE AND SERVICES 77
6.4.1 RISING UTILIZATION OF SOFTWARE FOR OPTIMAL IMAGE VISUALIZATION TO DRIVE MARKET 77
TABLE 21 CONTRAST-ENHANCED ULTRASOUND MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2021–2028 (USD MILLION) 78
7 CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION 79
7.1 INTRODUCTION 80
TABLE 22 CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 80
7.2 DIAGNOSTIC APPLICATIONS 80
TABLE 23 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 81
7.2.1 CARDIOLOGY 81
7.2.1.1 Increasing incidence of CVD to drive market 81
TABLE 24 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC CARDIOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 82
7.2.2 HEPATIC 82
7.2.2.1 Utilization of CEUS technology in characterization of focal liver lesions to drive market 82
TABLE 25 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC HEPATIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 82
7.2.3 NEPHROLOGY 83
7.2.3.1 Ability to identify renal complications to propel market 83
TABLE 26 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC NEPHROLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 83
7.2.4 OTHER DIAGNOSTIC APPLICATIONS 83
TABLE 27 CONTRAST-ENHANCED ULTRASOUND MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 84
7.3 THERAPEUTIC APPLICATIONS 84
TABLE 28 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 84
7.3.1 CARDIOLOGY 85
7.3.1.1 Growing applications in targeted drug delivery to propel market 85
TABLE 29 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC CARDIOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 85
7.3.2 VASCULAR 85
7.3.2.1 Growing use of contrast agents in blood flow dynamics to fuel market 85
TABLE 30 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC VASCULAR APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 86
7.3.3 ONCOLOGY 86
7.3.3.1 Rising utilization in targeted therapy to drive market 86
TABLE 31 CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC ONCOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 87
7.3.4 OTHER THERAPEUTIC APPLICATIONS 87
TABLE 32 CONTRAST-ENHANCED ULTRASOUND MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 87
8 CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER 88
8.1 INTRODUCTION 89
TABLE 33 CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021–2028 (USD MILLION) 89
8.2 HOSPITALS AND SURGICAL CENTERS 89
8.2.1 RISING NUMBER OF CEUS-BASED MEDICAL PROCEDURES TO DRIVE MARKET 89
TABLE 34 CONTRAST-ENHANCED ULTRASOUND MARKET FOR HOSPITALS AND SURGICAL CENTERS, BY REGION, 2021–2028 (USD MILLION) 90
8.3 DIAGNOSTIC IMAGING CENTERS 90
8.3.1 RISING ESTABLISHMENT OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH 90
TABLE 35 CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021–2028 (USD MILLION) 91
8.4 AMBULATORY SURGERY CENTERS 91
8.4.1 RISING VOLUME OF EMERGENCY SURGERIES TO PROPEL MARKET 91
TABLE 36 CONTRAST-ENHANCED ULTRASOUND MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2028 (USD MILLION) 92
8.5 OTHER END USERS 92
TABLE 37 CONTRAST-ENHANCED ULTRASOUND MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 92
9 CONTRAST-ENHANCED ULTRASOUND MARKET, BY REGION 93
9.1 INTRODUCTION 94
TABLE 38 CONTRAST-ENHANCED ULTRASOUND MARKET, BY REGION, 2021–2028 (USD MILLION) 94
9.2 NORTH AMERICA 94
FIGURE 23 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET SNAPSHOT 95
9.2.1 NORTH AMERICA: RECESSION IMPACT 96
TABLE 39 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 40 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 96
TABLE 41 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 97
TABLE 42 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 97
TABLE 43 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 97
TABLE 44 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 98
TABLE 45 NORTH AMERICA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021–2028 (USD MILLION) 98
9.2.2 US 98
9.2.2.1 High adoption rate of innovative medical technologies to drive market 98
TABLE 46 US: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99
TABLE 47 US: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 100
9.2.3 CANADA 100
9.2.3.1 Increasing incidence of heart & kidney diseases to drive market 100
TABLE 48 CANADA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 101
TABLE 49 CANADA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 101
9.3 EUROPE 101
9.3.1 EUROPE: RECESSION IMPACT 101
TABLE 50 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 51 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 102
TABLE 52 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 53 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 54 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 103
TABLE 55 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 103
TABLE 56 EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021–2028 (USD MILLION) 104
9.3.2 GERMANY 104
9.3.2.1 High healthcare expenditure to propel market 104
TABLE 57 GERMANY: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 105
TABLE 58 GERMANY: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 105
9.3.3 FRANCE 105
9.3.3.1 Rising target patient population and government-funded investments for advanced medical equipment to fuel uptake 105
TABLE 59 FRANCE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 106
TABLE 60 FRANCE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 106
9.3.4 UK 107
9.3.4.1 Increasing investments in diagnostic imaging to drive market 107
TABLE 61 UK: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 107
TABLE 62 UK: CONTRAST-ENHANCED ULTRASOUND FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 108
9.3.5 REST OF EUROPE 108
TABLE 63 REST OF EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 109
TABLE 64 REST OF EUROPE: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 109
9.4 ASIA PACIFIC 109
FIGURE 24 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET SNAPSHOT 110
9.4.1 ASIA PACIFIC: RECESSION IMPACT 110
TABLE 65 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 66 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 111
TABLE 67 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 68 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 69 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 70 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 71 ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.4.2 JAPAN 113
9.4.2.1 Presence of universal healthcare reimbursement system to support market growth 113
TABLE 72 JAPAN: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 114
TABLE 73 JAPAN: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 114
9.4.3 CHINA 114
9.4.3.1 Rising government initiatives for improvements in healthcare infrastructure to drive market 114
TABLE 74 CHINA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115
TABLE 75 CHINA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 115
9.4.4 INDIA 116
9.4.4.1 Growing public-private investments in novel medical technologies to drive market 116
TABLE 76 INDIA: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
TABLE 77 INDIA: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 117
9.4.5 REST OF ASIA PACIFIC 117
TABLE 78 REST OF ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 118
TABLE 79 REST OF ASIA PACIFIC: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 118
 
9.5 REST OF THE WORLD 118
9.5.1 REST OF THE WORLD: RECESSION IMPACT 119
TABLE 80 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119
TABLE 81 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET FOR CONTRAST AGENTS, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 82 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 120
TABLE 83 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 84 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 85 REST OF THE WORLD: CONTRAST-ENHANCED ULTRASOUND MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10 COMPETITIVE LANDSCAPE 122
10.1 OVERVIEW 122
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 122
FIGURE 25 CONTRAST-ENHANCED ULTRASOUND MARKET: KEY PLAYER STRATEGIES 123
10.3 REVENUE SHARE ANALYSIS 124
FIGURE 26 CONTRAST-ENHANCED ULTRASOUND MARKET: REVENUE SHARE ANALYSIS OF LEADING PLAYERS (2022) 124
10.4 MARKET SHARE ANALYSIS 124
FIGURE 27 CONTRAST-ENHANCED ULTRASOUND MARKET: MARKET SHARE ANALYSIS OF LEADING PLAYERS (2022) 124
TABLE 86 CONTRAST-ENHANCED ULTRASOUND MARKET: INTENSITY OF COMPETITIVE RIVALRY 125
10.5 COMPANY EVALUATION MATRIX (2022) 126
10.5.1 STARS 126
10.5.2 PERVASIVE PLAYERS 126
10.5.3 EMERGING LEADERS 126
10.5.4 PARTICIPANTS 126
FIGURE 28 CONTRAST-ENHANCED ULTRASOUND MARKET: COMPANY EVALUATION MATRIX (2022) 127
10.6 COMPETITIVE BENCHMARKING 128
TABLE 87 CONTRAST-ENHANCED ULTRASOUND MARKET: PRODUCT & REGIONAL FOOTPRINT ANALYSIS 128
10.7 COMPETITIVE SCENARIO AND TRENDS 128
10.7.1 PRODUCT LAUNCHES 128
TABLE 88 CONTRAST-ENHANCED ULTRASOUND MARKET: PRODUCT LAUNCHES (JANUARY 2020–JULY 2023) 128
10.7.2 DEALS 129
TABLE 89 CONTRAST-ENHANCED ULTRASOUND MARKET: DEALS (JANUARY 2020–JULY 2023) 129
10.7.3 OTHER DEVELOPMENTS 130
TABLE 90 CONTRAST-ENHANCED ULTRASOUND MARKET: OTHER DEVELOPMENTS (JANUARY 2020−JULY 2023) 130
11 COMPANY PROFILES 131
11.1 KEY PLAYERS 131
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 GE HEALTHCARE 131
TABLE 91 GE HEALTHCARE: COMPANY OVERVIEW 131
FIGURE 29 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 132
11.1.2 LANTHEUS 135
TABLE 92 LANTHEUS: COMPANY OVERVIEW 135
FIGURE 30 LANTHEUS: COMPANY SNAPSHOT (2022) 136
11.1.3 BRACCO IMAGING S.P.A. 139
TABLE 93 BRACC0 IMAGING S.P.A.: COMPANY OVERVIEW 139
11.1.4 KONINKLIJKE PHILIPS N.V. 142
TABLE 94 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 142
FIGURE 31 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 143
11.1.5 SIEMENS HEALTHINEERS 145
TABLE 95 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 145
FIGURE 32 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022) 146
11.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 149
TABLE 96 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 149
FIGURE 33 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022) 150
11.1.7 CANON INC. 152
TABLE 97 CANON INC.: COMPANY OVERVIEW 152
FIGURE 34 CANON INC.: COMPANY SNAPSHOT (2022) 153
11.1.8 ESAOTE S.P.A 155
TABLE 98 ESAOTE S.P.A: COMPANY OVERVIEW 155
11.1.9 SAMSUNG ELECTRONICS CO., LTD. 157
TABLE 99 SAMSUNG ELECTRONICS CO., LTD.: COMPANY OVERVIEW 157
FIGURE 35 SAMSUNG ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022) 158
11.1.10 GUERBET 160
TABLE 100 GUERBET: COMPANY OVERVIEW 160
FIGURE 36 GUERBET: COMPANY SNAPSHOT (2022) 161
11.2 OTHER PLAYERS 163
11.2.1 NANOPET PHARMA GMBH 163
11.2.2 BAYER AG 163
11.2.3 REVVITY 164
11.2.4 SOLSTICE PHARMACEUTICALS B.V. 164
11.2.5 TRIVITRON HEALTHCARE 165
11.2.6 LERIVA 165
11.2.7 JB PHARMA 166
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 167
12.1 DISCUSSION GUIDE 167
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 171
12.3 CUSTOMIZATION OPTIONS 173
12.4 RELATED REPORTS 173
12.5 AUTHOR DETAILS 174